Cyclopamine

Name: Cyclopamine
Brand: Selleck Chemicals
SKU: S1146
Rating: 5 (79 reviews)

For research use only.

Catalog No.S1146 Synonyms: 11-deoxojervine

79 publications

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Selleck's Cyclopamine has been cited by 79 publications

Nature, 2015, 10.1038/nature14325

PubMed: 25938716 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)418

PubMed: 33499351 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16313

PubMed: 33507617 ( click the link to review the publication )

J Orthop Surg Res, 2021, 16(1):160

PubMed: 33637095 ( click the link to review the publication )

Can J Physiol Pharmacol, 2021, 10.1139/cjpp-2020-0588

PubMed: 33617370 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2021, 62(2):33

PubMed: 33616621 ( click the link to review the publication )

Nat Commun, 2020, 11(1):44

PubMed: 31896750 ( click the link to review the publication )

Cell Rep, 2020, 21;31(3):107521

PubMed: 32320667 ( click the link to review the publication )

Int J Cancer, 2020, 7

PubMed: 32383186 ( click the link to review the publication )

Stem Cell Reports, 2020, S2213-6711(20)30192-2

PubMed: 32589876 ( click the link to review the publication )

J Clin Endocrinol Metab, 2020, dgaa656

PubMed: 32936899 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):488

PubMed: 33198821 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 20;2020:1868764

PubMed: 32377291 ( click the link to review the publication )

Proc Biol Sci, 2020, 287(1935):20192939

PubMed: 32933441 ( click the link to review the publication )

Chemosphere, 2020, 6;254:126709

PubMed: 32348926 ( click the link to review the publication )

Front Cell Neurosci, 2020, 14:575690

PubMed: 33343302 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6410

PubMed: 32899202 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Dev Biol, 2020, 457(1):128-139

PubMed: 31550483 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.2873

PubMed: 32030915 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2610-2620

PubMed: 33125122 ( click the link to review the publication )

Front Pharmacol, 2020, 11:204

PubMed: 32194421 ( click the link to review the publication )

Neural Plast, 2020, 2020:8815195

PubMed: 32802036 ( click the link to review the publication )

Dev Cell, 2019, 51(6):665-674.e6

PubMed: 31813796 ( click the link to review the publication )
J Cell Biol, 2019, 218(9):3134-3152

PubMed: 31371388 ( click the link to review the publication )

Elife, 2019, 8e50208

PubMed: 31482846 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31658643 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(6):896-911

PubMed: 30445456 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2058-2066

PubMed: 30317648 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(8)E1991

PubMed: 31018557 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5386-5395

PubMed: 30367510 ( click the link to review the publication )

J Cell Biochem, 2019, 120(11):18979-18994

PubMed: 31245876 ( click the link to review the publication )

Exp Cell Res, 2019, 385(2):111671

PubMed: 31634481 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2019, 124(6):660-669

PubMed: 30548093 ( click the link to review the publication )

Hepatobiliary Pancreat Dis Int, 2019, 18(1):38-47

PubMed: 30243878 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Neuron, 2018, 97(6):1235-1243

PubMed: 29526553 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30014845 ( click the link to review the publication )

Lab Chip, 2018, 18(20):3184-3195

PubMed: 30204194 ( click the link to review the publication )

Exp Cell Res, 2018, 366(1):63-70

PubMed: 29548749 ( click the link to review the publication )

Mol Pain, 2018, 14:1744806918767560

PubMed: 29607715 ( click the link to review the publication )

Biol Reprod, 2018, 98(4):480-490

PubMed: 29329377 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):21-30

PubMed: 29115520 ( click the link to review the publication )

Cell Transplant, 2018, 27(3):393-406

PubMed: 29749250 ( click the link to review the publication )

Nat Commun, 2017, 8:14382

PubMed: 28176763 ( click the link to review the publication )

PLoS Genet, 2017, 13(8):e1006951

PubMed: 28797033 ( click the link to review the publication )

Front Immunol, 2017, 9:2847

PubMed: 30568656 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )
Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):568-578

PubMed: 27709831 ( click the link to review the publication )

Exp Cell Res, 2017, 357(1):79-87

PubMed: 28461158 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 89:147-156

PubMed: 28624529 ( click the link to review the publication )

Mol Immunol, 2017, 92:68-75

PubMed: 29054053 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5605-5619

PubMed: 29200875 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42495-42509

PubMed: 28477008 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):682-94

PubMed: 27113760 ( click the link to review the publication )

J Med Chem, 2016, 59(24):11050-11068

PubMed: 27736063 ( click the link to review the publication )

Cell Biosci, 2016, 10.1186/s13578-016-0104-8

PubMed: 27313840 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:63

PubMed: 26048374 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2569-89

PubMed: 26609469 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Int J Mol Med, 2015, 35(6):1641-50

PubMed: 25872645 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(5):816-828

PubMed: 26527387 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):544-59

PubMed: 24553082 ( click the link to review the publication )

Eur J Pharmacol, 2014, 10.1016/j.ejphar.2014.01.074

PubMed: 24534491 ( click the link to review the publication )

Mol Cell Biochem, 2014, 396(1-2):257-68

PubMed: 25064451 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbadis.2014.10.001

PubMed: 25305367 ( click the link to review the publication )

Insect Sci, 2014, 10.1111/1744-7917

PubMed: 25154865 ( click the link to review the publication )

Dev Biol, 2013, 381(2):312-23

PubMed: 23872235 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 5;32(1):7

PubMed: 23379358 ( click the link to review the publication )

Toxicol Lett, 2013, 225(2):318-324

PubMed: 24388991 ( click the link to review the publication )
PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )

Neuro Oncol, 2012, 14(12):1441-51

PubMed: 23104476 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2262-74

PubMed: 22396494 ( click the link to review the publication )

Cancer Lett, 2012, 322(2):169-76

PubMed: 22450749 ( click the link to review the publication )

Exp Hematol, 2012, 40(5):418-27

PubMed: 22240607 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description

Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Targets

Smoothened ^[1]
(TM3Hh12 cells)

46 nM

In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [³H]Hh-Ag binding assay with an IC50 of 280 nM. ^[1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. ^[2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMO^high Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMO^low cell line. ^[3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
OS-RC-2	M1fEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFLySYtKSzVyPUWuPFY3PiEQvF2=	NEDacmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
DOHH-2	NX\yR4szT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIj3T4tKSzVyPUmuN\|U3QDlizszN	Mnn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
no-10	NYT5bG9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV2xfm5YUUN3ME25MlkxOzlizszN	NWnOPHpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LS-513	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MljxTWM2OD1zMT6zOVQ4KM7:TR?=	MmTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ALL-PO	NGPKcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M360[2lEPTB;MUGuO\|c{PCEQvF2=	MomxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
8-MG-BA	M2TPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnfRTWM2OD1zMz6xNVI{KM7:TR?=	NILsZXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
RPMI-8402	MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NILoUpZKSzVyPUG1Mlg2OzdizszN	NGe1W2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
EoL-1-cell	M1rRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmDXTWM2OD1zOD61PVQ5KM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NALM-6	NHHNSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYrJR\|UxRTF7LkCxOlch\|ryP	NWKwXnF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
DEL	NHfo[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWfJR\|UxRTJyLkG0O\|Eh\|ryP	NF3pbGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
SR	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MU\JR\|UxRTJ\|Lk[3NVUh\|ryP	Mn[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
697	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWDtPGUxUUN3ME2yOk43OTV3IN88US=>	M3XFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
COLO-829	NVTJOJhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEDWUXpKSzVyPUK2Mlg1QDNizszN	M1fUdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
EVSA-T	NF75TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWO4SFd4UUN3ME2yO{42PTZzIN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ATN-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFvHZ2VKSzVyPUOxMlI{OjlizszN	M1nvSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
L-363	NEDzNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4PsUGlEPTB;M{GuO\|Q3OSEQvF2=	M4D6bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LAMA-84	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoO3TWM2OD1\|Mj61NlEyKM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NOS-1	NVPKcGhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFfQSG5KSzVyPUO0MlI6PTZizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
BB30-HNC	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MULJR\|UxRTN2LkOzNFYh\|ryP	NGrmTm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
BC-1	M3HSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVf6W49HUUN3ME2zO{46PzR4IN88US=>	NI\GcVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
IST-SL2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGPhRXJKSzVyPUO4MlIzPCEQvF2=	NVn5T2NNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
D-392MG	NEj5RnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYr1NYx3UUN3ME20NE4zOjF3IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
no-11	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M33KfGlEPTB;NECuOVUzOSEQvF2=	Mn3XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LC4-1	NHTjNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MY\JR\|UxRTRyLki3NVYh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
A388	NYX0UZZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmLyTWM2OD12Mj61PFQ5KM7:TR?=	MlfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	NEDK[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYjWPHZTUUN3ME20Nk44ODd2IN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
CESS	NIqySZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHqzZVNKSzVyPUS0MlIzOzJizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
RS4-11	M4XrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVG1NpJNUUN3ME20PU4xQTN6IN88US=>	MljvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MS-1	M2Wyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn32TWM2OD13MD65N\|UyKM7:TR?=	MmXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
CTV-1	M3rDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4\ucWlEPTB;NUGuNFc1KM7:TR?=	Mki0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
D-502MG	NWS2N\|Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIDGUXZKSzVyPUWxMlYzPzFizszN	NX7BVW5ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ML-2	NWPpPHZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUC4OlR7UUN3ME21Nk46OTl3IN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
SK-NEP-1	MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4\OfmlEPTB;NUOuN\|kzOyEQvF2=	NVe2cIxtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LOXIMVI	NH[1c45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEnTWIJKSzVyPUWzMlU5QDRizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
DJM-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3;TV2lEPTB;NU[uN\|M6OSEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
GI-1	NHThbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYD5bHpuUUN3ME21Ok43OTR7IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
IST-MES1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn3LTWM2OD14MD61OFk{KM7:TR?=	NFHXb5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MV-4-11	NYLPNGNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1S1UWlEPTB;NkCuOlU{QCEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
OVCAR-4	NXXXT4Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX\JR\|UxRTZ\|LkW2OVch\|ryP	M{LMdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KE-37	NUDJNHhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml;2TWM2OD14Nj6yOlY5KM7:TR?=	NYLz[HRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
D-542MG	MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1flXGlEPTB;NkiuOFE{PSEQvF2=	NYPGSo93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MHH-PREB-1	NXLmSWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmTMTWM2OD15Mj64OFQyKM7:TR?=	M3PKV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MRK-nu-1	NGXV[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHu5NnlKSzVyPUezMlQ4ODVizszN	NUnwO4NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
D-247MG	NHHGbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX7JR\|UxRTd\|LkW0OFIh\|ryP	M2n4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
OCI-AML2	MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoC4TWM2OD15Nj65N\|Y6KM7:TR?=	NFXJe2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LP-1	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFXPUJJKSzVyPUiyMlg4OzFizszN	Ml23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HCC1599	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUTJR\|UxRTh2LkK4N\|ch\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KARPAS-45	NVvVSVI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGfUZWFKSzVyPUi0MlY6QTJizszN	M2HmWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
BE-13	NHTmXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1nUb2lEPTB;OUmuNFQ4PyEQvF2=	M3fs[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
GCIY	M2nGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{nmSGlEPTB;OUmuNFk2PCEQvF2=	M3u5U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
BV-173	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnHCTWM2OD1zMECuN\|I2KM7:TR?=	M3;BPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LB2518-MEL	Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoO3TWM2OD1zMECuO\|g6KM7:TR?=	NFj3S449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KS-1	MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NILkRY5KSzVyPUGwNU43OzlizszN	NEP5WlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MOLT-16	NGDFW\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYPvOHFZUUN3ME2xNFQvQTh4IN88US=>	NIWyNYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H1770	NYXVOllkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVXnNZhMUUN3ME2xNFgvPzh2IN88US=>	NH3FcnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H82	NGe0UmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYrJR\|UxRTFzMD65O\|Yh\|ryP	NULJeGRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCCIT	NFThRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUTzZlVWUUN3ME2xNVIvPTJ7IN88US=>	M4fWcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KALS-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV7kc2NKUUN3ME2xNVUvQTRzIN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LB2241-RCC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmfjTWM2OD1zMU[uOlc6KM7:TR?=	NYnSWXZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HH	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4jhNWlEPTB;MUG3MlM6PSEQvF2=	NH:xNpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HD-MY-Z	NGmxeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYnUdHR6UUN3ME2xNVgvPDh6IN88US=>	Mk\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
EB-3	NFeyfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIf2R2RKSzVyPUGyN{4xQTRizszN	Mn;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BL-70	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH;BR5BKSzVyPUGyN{4yOjdizszN	NXTJS4hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
K-562	M{PaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mlz1TWM2OD1zMk[uNlQ2KM7:TR?=	M{HZcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HT-144	M{HTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUTJR\|UxRTF\|Mz6xOlQh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
PF-382	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV7JR\|UxRTF\|ND6zOlEh\|ryP	NHzucG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
RPMI-8226	MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlTwTWM2OD1zM{WuNFQ2KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-H1355	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIP5fYJKSzVyPUGzOU42QDdizszN	M2XudVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LXF-289	MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M33jWmlEPTB;MUO5Mlc5OSEQvF2=	NWP3eWFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H69	M4KwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXLJR\|UxRTF2Mj65N\|Ih\|ryP	MmrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	NWLmWot5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH3wXWRKSzVyPUG0O{4yOyEQvF2=	NUDyfHYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KARPAS-299	Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYLJR\|UxRTF2OT6xNkDPxE1?	NGe5Om09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
GB-1	NXnxSmR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHv6V2VKSzVyPUG0PU4{OjJizszN	NF;ofJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
CMK	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYK2do5RUUN3ME2xOFkvPTF3IN88US=>	NUjHNY1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MPP-89	NYXnbFdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3TOO2lEPTB;MUW2MlA{PSEQvF2=	Mm\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KU812	NVXUXHg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX;TOYk6UUN3ME2xOlEvQTB{IN88US=>	M4LNRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
REH	NWPId5plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{j0eWlEPTB;MU[yMlEzPSEQvF2=	M1f2O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NEC8	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2PVS2lEPTB;MU[1MlAzPiEQvF2=	NXXIWVlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KP-N-YS	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NULxd\|d2UUN3ME2xOlgvOzl3IN88US=>	MmLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWTRb5JFUUN3ME2xOlkvQTF3IN88US=>	NHvzTXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
Becker	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXPQeGdsUUN3ME2xO\|QvOThizszN	MkDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LB647-SCLC	NHHadVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M17BZWlEPTB;MUe1Mlg1PSEQvF2=	NWPPW3lHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LU-139	NEPTUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NISwTo9KSzVyPUG3PE4xOTlizszN	MlG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	NECweJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3XHUWlEPTB;MUe5MlY1PiEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-H1395	NUjUb257T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoLJTWM2OD1zN{muPVk3KM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NOMO-1	NW\IZm9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MknHTWM2OD1zOEKuPFUh\|ryP	M1fu[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
GI-ME-N	NEfqZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXfRVVNOUUN3ME2xPFcvQTZ7IN88US=>	M3nx[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KMS-12-PE	NFn3NlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWDJR\|UxRTF6OT6yO\|Mh\|ryP	NEfZOHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
Daudi	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGrUU5hKSzVyPUG5NU4yOjhizszN	M1XYNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LB996-RCC	NWn3SFM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWTodmZGUUN3ME2xPVEvPjl7IN88US=>	MlfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H2107	NFzFSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVvJR\|UxRTF7Mz63N\|kh\|ryP	NVTac4VrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
SK-PN-DW	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIPWR2lKSzVyPUG5OE44OTlizszN	NXX5bXZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MC-CAR	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{iyVWlEPTB;MkCyMlI2OyEQvF2=	M1n5XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SNB75	M4jhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYPJR\|UxRTJ{MT65OEDPxE1?	MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ES4	M1nZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWDJR\|UxRTJ{Mz63PFMh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KARPAS-422	NHi5cldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NITMVY5KSzVyPUKyPE4{PTJizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-H1648	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXfJR\|UxRTJ{OT60PFkh\|ryP	M{CwW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
ES6	M{jtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVvJR\|UxRTJ\|OT60N{DPxE1?	NH[yeXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KNS-81-FD	NH3QdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MknSTWM2OD1{NEGuNVk4KM7:TR?=	NHTtUok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
JAR	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnzLTWM2OD1{NU[uNlI2KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NB1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVq5em5KUUN3ME2yOlAvPTF4IN88US=>	MmXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
D-336MG	Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4nFbWlEPTB;Mk[wMlY6QCEQvF2=	NU\yOmJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
BC-3	NX\IWZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlvSTWM2OD1{NkWuNVc5KM7:TR?=	M3PkcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HCC2218	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoPHTWM2OD1{Nk[uOFE2KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
TE-9	NUHNUmE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mmq1TWM2OD1{Nk[uOlI4KM7:TR?=	NVv2PZppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LB1047-RCC	NYL3d\|RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGfKfIZKSzVyPUK2Ok44PTNizszN	NF;1Vow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
CTB-1	M4S0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3:yXGlEPTB;Mk[5Mlk4OyEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NB7	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVTJR\|UxRTJ5MTFOwG0>	NFO0PJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ST486	M1vPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXjWTHd5UUN3ME2yO\|cvPDF{IN88US=>	NFjUOXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HCC1187	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4LS[mlEPTB;MkiyMlgyOSEQvF2=	M3zSNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NCI-SNU-16	NFH6NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmjDTWM2OD1{OESuNlQ5KM7:TR?=	M1K2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
COR-L279	NYLKW\|BZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{D1XGlEPTB;MkmxMlU5PCEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ES8	NYH1eFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWPJR\|UxRTJ7ND6xPFIh\|ryP	Mmq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
U-698-M	NYXVTpQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEfMOJJKSzVyPUK5PE4zPDNizszN	NY\EdmxvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HEL	NIjvc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoXETWM2OD1\|MEmuNVQ6KM7:TR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KINGS-1	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWjJR\|UxRTNzMD62O\|Qh\|ryP	NIPyT2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KY821	NH;0R2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYTJR\|UxRTN\|Nj61PVUh\|ryP	M3jCOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MZ1-PC	M{jB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml74TWM2OD1\|NEWuOlE5KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LS-411N	NHrwSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlfPTWM2OD1\|NUSuOlYh\|ryP	Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SIG-M5	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1\jXWlEPTB;M{W5Mlc5OiEQvF2=	NVfIVW9SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HT	NHWyXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGjwfY5KSzVyPUO2O{44OTFizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HC-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NW\U[G9IUUN3ME2zOlcvPzh5IN88US=>	NUKzfFk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H1694	NXW0TodvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVPJR\|UxRTN5Mj65N\|Qh\|ryP	NXLDN4dRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
BB65-RCC	NIj1PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX;vOIZXUUN3ME2zO\|YvOjR3IN88US=>	M2K4ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HAL-01	M4j2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3qxXmlEPTB;M{e5Mlg{QCEQvF2=	NXnpRWpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ARH-77	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2\DNWlEPTB;M{m0MlAxQCEQvF2=	MlH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MZ7-mel	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MljuTWM2OD1\|OUeuNlM{KM7:TR?=	NYPCW5NVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
SIMA	M3LuN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX;JR\|UxRTRyMz65N\|Mh\|ryP	NY\ZZodtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
DG-75	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVXT[FBrUUN3ME20NVUvPjl6IN88US=>	M3TkUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HUTU-80	MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXXJR\|UxRTRzOT6xPFUh\|ryP	NULnU41CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KNS-42	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MU\JR\|UxRTR{NT64NVUh\|ryP	M3vle\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SH-4	NWDEVZhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHuzNpRKSzVyPUSyO{42PjVizszN	NGO4V489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
L-540	NXqzO2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVLJR\|UxRTR\|MT6wN\|Eh\|ryP	NYrnfow5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NB10	Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIXrU4xKSzVyPUS0NU4zOzRizszN	NFr0SnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ES1	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUjJR\|UxRTR3Mj63OVMh\|ryP	NFi4dFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KMOE-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUT2V2hUUUN3ME20OVYvPzFzIN88US=>	NFLsbJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MC116	NYizdGtPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXrEOmUxUUN3ME20OVgvOTF4IN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
RCC10RGB	NUnZRXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml6zTWM2OD12NkCuNFA2KM7:TR?=	M3\pWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
RL95-2	M3;QT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFzmW5hKSzVyPUS2NE4zOzdizszN	NEHz[\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
Raji	Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUfJR\|UxRTR4OD6xOFMh\|ryP	NHfXb409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
CAS-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1H4[GlEPTB;NEeyMlA4OyEQvF2=	NWrQUFJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
Calu-6	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUfJR\|UxRTR5NT6yOlUh\|ryP	NWG4XXdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KG-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXrERo15UUN3ME20O\|gvPDRizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LB771-HNC	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYHJR\|UxRTR6Mj6yN\|Ih\|ryP	NHnhbVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ACN	NFXMXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGr1VI5KSzVyPUS5N{42QTlizszN	NV:0epFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KM12	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUDJR\|UxRTR7Nj61PFkh\|ryP	MnH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
U2OS	MlPqSpVv[3Srb36gZZN{[Xl?			NFK5TW5DcW6maX7nJIFn\mmwaYT5JJRwKHerbHSgeJlx\SCVbX:g[ZhxemW\|c3XkJIlvKFV{T2OgZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3SgQUAxNjBzMkSg{txONg>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-
U2OS	MnTQSpVv[3Srb36gZZN{[Xl?		M4Owe\|IhcHK\|	NWXzc5lKTGm\|cHzhZ4Vu\W62IH;mJHs{UF2leXPsc5BidWmwZTDmdo9uKHerbHSgeJlx\SCVbX:g[ZhxemW\|c3XkJIlvKFV{T2OgZ4VtdHNiYX\0[ZIhOiCqcoOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygT4khRSByLkCxNlch\|ryPLh?=	NVjPUXJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
TM3	M1TqTmZ2dmO2aX;uJIF{e2G7		M2jJcVQ5KGi{cx?=	NIjUZWJKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIGTNN{Bk\WyuczDi[YFzcW6pIIDURU05gEeuaT3MeYMhemWyb4L0[ZIh[2:wc4TyeYN1KGG\|c3Xzd4VlKGG\|IITyZY5{[3KrcITpc45idCCvb3T1cIF1cW:wIH;mJGdtcSCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SCjc4PhfUwhUUN3MDC9JFAvODR4IN88UU4>	NFvj[WU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC5NVU2QSd-MUmwPVE2PTl:L3G+
HCC827	MoHRSpVv[3Srb36gZZN{[Xl?			MYDEbZNxdGGlZX3lcpQhd2ZiW{PIYU1kgWOub4DhcYlv\SCocn;tJHNOVyCYNEC0UUBufXSjboSgbY4h\2WoaYTpcoljKHKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3mgQUAxNjB3MTFOwG0v	Mor3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5OEexOVYoRjJ6N{i3NVU3RC:jPh?=
HEK293	NGP5UXRHfW6ldHnvckBie3OjeR?=		MmHONkBpenN?	MXLEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NWyjYnXscIVlKGO7Y3zvdIFucW6nIH\yc40hcHWvYX6gV41wKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweHluIFnDOVAhRSByLkC2OEDPxE1w	M2fBWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
Shh Light2	MnXmSpVv[3Srb36gZZN{[Xl?		NFyxWpk{OCCqcoO=	M3j6bmlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViU3joJGxq\2i2MjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHOxbnnjJIhm\GenaH;nMYlv\HWlZXSgS2xKOS2vZXTpZZRm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkhdWWjc4Xy[YQh[W[2ZYKgN\|AhcHK\|IHL5JIR2[WxibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xPzRzIN88UU4>	MmHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NkezO\|EoRjJ5NU[3N\|cyRC:jPh?=
U2OS	NIjyNmNHfW6ldHnvckBie3OjeR?=			MYjCbY5lcW6pIHHm[olvcXS7IITvJHNudyCGNEezTEBufXSjboSg[ZhxemW\|c3XkJIlvKFV{T2OgZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3SgQUAxNjFzNjFOwG0v	NF7RW3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N\|UzOid-MkOwOlM2OjJ:L3G+
DaOY	MW\GeY5kfGmxbjDhd5NigQ>?		M{[zdFQ5KGi{cx?=	NET1RllKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBpfW2jbjDEZW9[KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaUGgcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDR6IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjF4IN88UU4>	M4LqfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|E3Lz5{NEmwNFcyPjxxYU6=
U2OS	MUTGeY5kfGmxbjDhd5NigQ>?		M3vsRVIhcHK\|	NEj1[mdFcXOybHHj[Y1mdnRib3[gX\|NJZWO7Y3zvdIFucW6nIH\yc40hW22xIFS0O\|NJKG23dHHueEBmgHC{ZYPz[YQhcW5iVULPV{Bk\WyuczDh[pRmeiB{IHjyd{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBMcSB;IECuNlMzKM7:TT6=	MknCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=
CHO	MnPUSpVv[3Srb36gZZN{[Xl?			NX35SYlySW62YXfvcol{fCCjY4Tpeol1gSCjdDDoeY1idiCVbX:gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKEOKTzDj[YxteyCkeTDbN2heUGhvQXegZolv\GmwZzDhd5NigSxiSVO1NEA:KDBwMkig{txONg>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB7MUW1PUc,OTlyOUG1OVk9N2F-
Shh Light2	NEDqTG9HfW6ldHnvckBie3OjeR?=		NXTzTnF4PDBiaILz	NHjPVFBKdmirYnn0bY9vKG:oIGPITEBx[XSqd3H5JIlvKG2xdYPlJHNpcCCOaXfoeFIh[2WubIOgZYZ1\XJiNECgbJJ{KGK7IFfsbU1l\XCnbnTlcpQhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6zJO69VS5?	NGHMfYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW5Nlc5QCd-MkG1PVI4QDh:L3G+
Shh-light2	MXTGeY5kfGmxbjDhd5NigQ>?			MUfJcohq[mm2aX;uJI9nKFOvbz3t[YRq[XSnZDDIbEB{cWewYXzpcochcW5iaIXtZY4hW2iqLXzp[4h1OiClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlMh\|ryPLh?=	M3fxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
M210B4	MkDuSpVv[3Srb36gZZN{[Xl?		NGTV[YwzPCCqcoO=	NXvVZ2FZUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hdW:3c3WgUVIyOEJ2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve45z\We3bHH0bY9vKG:oIGD0Z4ghdVKQQTDlfJBz\XO\|aX;uJIFnfGW{IEK0JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXNuIFnDOVAhRSByLkSzJO69VS5?	MomwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
Shh-Light 2	M2PS[mZ2dmO2aX;uJIF{e2G7		NF\0NZAzKGSjeYO=	NEDuRoRCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IGPtc{BqdiCvb4Xz[UBUcGhvTHnnbJQhOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNpcC2rbnT1Z4VlKEeuaUGtdoVxd3K2ZYKgZYN1cX[rdImgZYZ1\XJiMjDkZZl{KGK7IHT1ZYwudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJI1mfGixZDygTWM2OCB;IECuOFg1KM7:TT6=	NYnwSIM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
Shh Light2	M2\Zd2Z2dmO2aX;uJIF{e2G7			NXXVbWpiUW6qaXLpeIlwdiCxZjDTTGghcW5ibX;1d4UhW2iqIFzp[4h1OiClZXzsd{BjgSCJTFmtdoV{eG:wc3n2[UBncXKnZnz5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwNTFOwG0v	M3i4W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{C5NFgxLz5zOUOwPVA5ODxxYU6=
C3H10T1/2	Mo\vSpVv[3Srb36gZZN{[Xl?			MmTzTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIGPITEBi[3SrdnH0[YQheGG2aIfhfUBqdiCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgZZN{\XO\|ZXSgZZMhW0GJLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36gZpkh[WytYXzpcoUheGixc4DoZZRie2ViYYPzZZktKEmFNUCgQUAxNjZizszNMi=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV7Mke4PEc,OjF3OUK3PFg9N2F-
C3H10T1/2	MXPGeY5kfGmxbjDhd5NigQ>?		MYq2JIhzew>?	MXXJcohq[mm2aX;uJI9nKFODRz3pcoR2[2WmIHTp[oZmemWwdHnheIlwdiCxZjDtc5V{\SCvZYPlcoNpgW2jbDDwcJVzcXCxdHXueEBEO0hzMGSxM\|Ih[2WubIOgeI8h[WytYXzpcoUheGixc4DoZZRie2VicH;zbZRqfmVib3Xz[Y9jdGG\|dIOgZYZ1\XJiNjDodpMtKEmFNUCgQUAxNjZ{IN88UU4>	NFP1Sow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFU2OSd-MkKyOlg2PTF:L3G+
ASZ001	M4nzTGZ2dmO2aX;uJIF{e2G7		MmP4OFghcHK\|	NHjmWItKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBud3W\|ZTDBV3oxODFiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiR3zpNUBuWk6DIHX4dJJme3Orb36gZYZ1\XJiNEigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyxiSVO1NEA:KDBwNk[g{txONg>?	NX74OpkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OTZpPkK0PVAxPzF4PD;hQi=>
M210B4	NXm3c3NRTnWwY4Tpc44h[XO\|YYm=		NEjaZYczPCCqcoO=	MlrxTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gcY92e2ViTUKxNGI1KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaUGgcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjhizszNMi=>	NFqwc5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
medulloblastoma cells	M2f4WGFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKG2nZIXscI9jdGG\|dH;tZUBk\WyuczDoZZJjd3KrbnegbIV1\XKxeonnc5V{KHC2Y3ixJIdmdmViYomgUXRVKGG\|c3H5MEBGSzVyIE2gNUDPxE1w	MnXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2MUe2N\|EoRjF5NEG3OlMyRC:jPh?=
CHO	MYXGeY5kfGmxbjDhd5NigQ>?			M2\PTGFvfGGpb37pd5Qh[WO2aY\peJkh[XRibX;1d4UhW22xIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[nliW{PIYWhpNUGpIHLpcoRqdmdiYYPzZZktKEmFNUCgQUAyNjJizszNMi=>	NF\IZ5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC5NVU2QSd-MUmwPVE2PTl:L3G+
Shh-Light2	NFLMS5ZHfW6ldHnvckBie3OjeR?=		NELke2c1QCCqcoO=	M3[zZWlvcGmkaYTpc44hd2ZiU1jIJIlvKG2xdYPlJHNpcC2OaXfoeFIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFfsbVEhemWyb4L0[ZIh\2WwZTDhd5NigSCrbjDwdoV{\W6lZTDv[kBUSUduIFnDOVAhRSBzLkOxNkDPxE1w	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV2MUS5NEc,OTl3NEG0PVA9N2F-
MEF	NUTvNJhITnWwY4Tpc44h[XO\|YYm=			MVrJcohq[mm2aX;uJI9nKFOvbzDpckBud3W\|ZTDQeINpNWSnZnnjbYVvfCCPRV[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVaHitbY5lfWOnZDDHcIkyKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUwhUUN3MDC9JFEvPSEQvF2u	M4HVWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEe0OVQyLz5{M{C3OFU1OTxxYU6=
MEF	MnPySpVv[3Srb36gZZN{[Xl?		MnzSN\|AhcHK\|	MoTsTY5pcWKrdHnvckBw\iCVbX:gbY4hdW:3c3WgVJRkcC2mZX\pZ4lmdnRiTVXGJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiU3joMYlv\HWlZXSgS4xqNXKnc4DvcpNqfmViYnX0ZYdidGGldH;zbYRie2ViYXP0bZZqfHliYX\0[ZIhOzBiaILzJIJ6KEKndHHHUI8h[XO\|YYmsJGlEPTBiPTCxMlkh\|ryPLh?=	NVfidIo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwO\|Q2PDFpPkKzNFc1PTRzPD;hQi=>
neural precursor cells	NF;Kd2VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKG6ndYLhcEBxemWldYLzc5Ih[2WubIOgZpkh[2:ub375JIZwem2jdHnvckBie3OjeTygSWM2OCB;IEGzMlQ1KM7:TT6=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzN{[zNUc,OTd2MUe2N\|E9N2F-
U87	NHz2RpBEgXSxdH;4bYNqfHliYYPzZZk>			NUH1XmRoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTh5IHPlcIx{KGG\|c3Xzd4VlKGG\|II\pZYJqdGm2eTDpckBxemW\|ZX7j[UBw\iCkZYThJIdtfWO3cn;ubYRie2VuIFnDOVAhRSBzNT61JO69VS5?	NEXhcZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGxOlkxPCd-MkCxNVY6ODR:L3G+
U87MG	M{LBVWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2XHWVczKGi{cx?=	NX7ZZY9vSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNlIvPSEQvF2u	NGfx[489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKyOlY2Pyd-MkKyNlY3PTd:L3G+
A549	M{fpNmFvfGmlYX7j[ZIh[XO\|YYm=			NXjPW4x3SW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iNEmg{txONg>?	M13aUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkKxPFczLz5zOEKyNVg4OjxxYU6=
DU145	NIPxe5BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXzCRZFEPSC3TR?=	MXi5OkBpenN?	M3Hj[Wdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGG2IEWgeW0h[W[2ZYKgPVYhcHK\|	NF7wSYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0PVEzPSd-MUiyOFkyOjV:L3G+
DU145	NGjWWXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mkf4NVAhfU1?	MVi5OkBpenN?	Mmf1S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[XRiMUCgeW0h[W[2ZYKgPVYhcHK\|	MnnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEmxNlUoRjF6MkS5NVI2RC:jPh?=
HEK293	NVrseVlOTnWwY4Tpc44h[XO\|YYm=			MkPWTY5pcWKrdHnvckBw\iCkZYThJIdidGGldH;zbYRie2ViaX6gTGVMOjl\|IHPlcIx{	MmnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OUS3OlYoRjF5NEm0O\|Y3RC:jPh?=
22Rv	NXXlXpJSTnWwY4Tpc44h[XO\|YYm=			M{DoTXJm\HWldHnvckBw\iCneIDy[ZN{cW:wIH;mJHBVS0hibWLORUBqdiCqdX3hckAzOlK4IHPlcIx{	M{DIZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEm0O\|Y3Lz5zN{S5OFc3PjxxYU6=
PANC1	NI\MUItHfW6ldHnvckBie3OjeR?=	MYCwMlIhfU1?	Mn\tNlQhcHK\|	NGrRboxKdmirYnn0bY9vKG:oIFjoM2dNUTFvbXXkbYF1\WRiUGTDTEBuWk6DIHX4dJJme3Orb36gbY4hcHWvYX6gVGFPSzFiY3XscJMh[XRiMD6yJJVOKGGodHXyJFI1KGi{czDifUBTXC2SQ2K=	M2HSe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEWwNVcxLz5{MES1NFE4ODxxYU6=
PANC1	M1m4XmZ2dmO2aX;uJIF{e2G7	M2rPflAvPCC3TR?=	MXqyOEBpenN?	M1TUdGlvcGmkaYTpc44hd2ZiSHivS2xKOS2vZXTpZZRm\CCSVFPIJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDQRW5EOSClZXzsd{BifCByLkSgeW0h[W[2ZYKgNlQhcHK\|IHL5JHJVNVCFUh?=	MlTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NUCxO\|AoRjJyNEWwNVcxRC:jPh?=
Shh Light2	NYm2dIdQTnWwY4Tpc44h[XO\|YYm=	NGraS3c3NjJ3IIXN	NIPpUXA{OCCqcoO=	MmW4TY5pcWKrdHnvckBw\iCQLYDhcI1qfG:7bHH0[YQhW2iqIHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiYYSgOk4zPSC3TTDh[pRmeiB\|MDDodpMh[nliZnny[YZtgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYm=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF3MUezNUc,OTlzNUG3N\|E9N2F-
U87MG	Ml\PSpVv[3Srb36gZZN{[Xl?	MXOxNEB2VQ>?	Mn6yOEBpenN?	MliwTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDoeY1idiCXOEfNS{Bk\WyuczDhd5Nme3OnZDDhd{Bld3ewIILl[5Vt[XSrb36gc4YhT2yrMTDheEAyOCC3TTDh[pRmeiB2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZM>	NU\kOpM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNlY3PTdpPkKyNlI3PjV5PD;hQi=>
HEK293	NVLmXHNqTnWwY4Tpc44h[XO\|YYm=	MUW1JJVO	MkTwNVAhcHK\|	NFK3XndFcXOybHHj[Y1mdnRib3[gRm9FUVC\LXP5Z4xweGGvaX7lJIZzd21iaIXtZY4hW22xIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYSgOUB2VSCvZXHzeZJm\CCjZoTldkAyOCCqcoOgZpkhTEGSSTDzeIFqdmmwZzDiZZNm\CCobIXvdoV{[2WwY3WgcYlkem:\|Y3;wbYMh[XO\|YYm=	NYmzTY5bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3N\|YxPjNpPkK3O\|M3ODZ\|PD;hQi=>
HEK293	NVqw[m9HTnWwY4Tpc44h[XO\|YYm=	Mn\hOUB2VQ>?	NEPPcZMyOCCqcoO=	NUnzR25NTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3jfYNtd3CjbXnu[UBnem:vIHj1cYFvKFOvbzDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHH0JFUhfU1ibXXhd5Vz\WRiYX\0[ZIhOTBiaILzJIJ6KE[DQ2OgZY5idHm\|aYO=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd\|NkC2N{c,Ojd5M{[wOlM9N2F-
C3H10T1/2	NHq1WlBHfW6ldHnvckBie3OjeR?=	NUPIN5pnPTVwNTD0c{A1PTByIH7N		Mof1R49ueGW2aYTpeoUhcW6qaXLpeIlwdiCxZjDTcY8hcW5ibX;1d4UhSzOKMUDUNU8zKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV2FINWmwZIXj[YQhT2yrMTD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYYSgOVUvPSC2bzC0OVAxKG6PIHL5JJFRS1JiYX7hcJl{cXN?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5NEW0NUc,OjNyN{S1OFE9N2F-
U2OS	MXjGeY5kfGmxbjDhd5NigQ>?	NUfwNnJEPSC3TR?=	MljsOkBpenN?	NH;wVINCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHPobY1memmlIGPtc{A3OzNibYX0ZY51KGW6cILld5Nm\CCrbjDVNm9UKGOnbHzzJINw\XiycnXzd4lv\yCkZYThJIFzemW\|dHnuNk1ITlBiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCrboTyZYNmdGy3bHHyJIJmfGFiYYLy[ZN1cW5{LVfGVEBi\2e{ZXfheIUh\m:{bXH0bY9vKGG2IEWgeW0h[W[2ZYKgOkBpenNiYomgZ49v\m:lYXygcYlkem:\|Y3;wfS=>	NIjk[5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N\|UzOid-MkOwOlM2OjJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	NF-κB / Cyclin D1 / MMP2 / MMP9; PubMed: 23599805 Oncol Lett Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9. Gli1 / TGF-β1 / CXCR4; PubMed: 26137001 Oncol Lett Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h. Snail / E-cadherin / Slug / Vimentin ; PubMed: 26859575 Oncotarget SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT.	23599805 26137001 26859575
Immunofluorescence	Vimentin; PubMed: 24553082 Cancer Biol Ther Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry. PCNA / β-catenin; PubMed: 28747625 Sci Rep Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times.	24553082 28747625

In vivo

Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. ^[2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMO^low tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Hedgehog cell assay: This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO₂. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO₂. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:^[2]	- Collapse Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116 Concentrations: Dissolved in DMSO, final concentration 3 μM Incubation Time: 4 days Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD₄₉₀) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2). (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells Dosages: 50 mg/kg/day Administration: Subcutaneous injection (Only for Reference)

References

[4] Feldmann G, et al. Cancer Res, 2007, 67(5), 2187-2196.

- Collapse

Solubility (25°C)

In vitro	DMF	10 mg/mL warmed (24.29 mM)
	Ethanol	2 mg/mL warmed (4.85 mM)
	DMSO	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Cyclopamine SDF

Molecular Weight	411.62
Formula	C₂₇H₄₁NO₂
CAS No.	4449-51-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	11-deoxojervine
Smiles	CC1CC2C(C(C3(O2)CCC4C5CC=C6CC(CCC6(C5CC4=C3C)C)O)C)NC1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo use in mice?
Answer:
One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Selective Smoothened inhibitor

PF-5274857 : Smoothened-selective, IC50=5.8 nM.
Smoothened Inhibitor in Clinical Trial

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
Newest Smoothened Inhibitor

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened Activator

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

Related Hedgehog/Smoothened Products

Smoothened Agonist (SAG) HCl ^New

Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.
SB225002 ^New

SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.
SB-334867 ^New

SB-334867 is a selective orexin-1 (OX1) receptor antagonist.
Vismodegib (GDC-0449)

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
GANT61

GANT61 (NSC 136476) is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation. GANT61 induces apoptosis and activates protective autophagy in LX-2 cells.
Purmorphamine

Purmorphamine (Shh Signaling Antagonist VI), which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM. Purmorphamine can reduce both basal and induced autophagy.
Sonidegib (NVP-LDE225)

Sonidegib (Erismodegib, NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.
Taladegib (LY2940680)

Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. Phase 1/2.
Glasdegib (PF-04449913)

Glasdegib (PF-04449913) is a potent, and orally bioavailable Smoothened (Smo) inhibitor with IC50 of 5 nM. Phase 2.
SANT-1

SANT-1 directly binds to Smoothened (Smo) receptor with K_d of 1.2 nM and inhibits Smo agonist effects with IC50 of 20 nM.

Features:Attenuates SAG stimulation of Shh-LIGHT2 cells to a greater extent relative to other antagonists.

Choose Your Country or Region

By Signaling Pathways

By product type

Cyclopamine